Kennedy Capital Management LLC purchased a new stake in shares of Stryker Co. (NYSE:SYK – Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 2,675 shares of the medical technology company’s stock, valued at approximately $957,000.
Other large investors have also recently made changes to their positions in the company. Aspen Investment Management Inc raised its stake in shares of Stryker by 0.7% in the first quarter. Aspen Investment Management Inc now owns 4,368 shares of the medical technology company’s stock worth $1,563,000 after purchasing an additional 31 shares during the last quarter. Harbor Investment Advisory LLC increased its holdings in Stryker by 0.4% in the 1st quarter. Harbor Investment Advisory LLC now owns 6,982 shares of the medical technology company’s stock worth $2,499,000 after acquiring an additional 31 shares in the last quarter. Proficio Capital Partners LLC raised its position in Stryker by 2.4% during the first quarter. Proficio Capital Partners LLC now owns 1,418 shares of the medical technology company’s stock worth $507,000 after acquiring an additional 33 shares during the period. Consolidated Portfolio Review Corp lifted its position in shares of Stryker by 3.6% in the fourth quarter. Consolidated Portfolio Review Corp now owns 983 shares of the medical technology company’s stock valued at $294,000 after acquiring an additional 34 shares in the last quarter. Finally, FourThought Financial Partners LLC boosted its stake in shares of Stryker by 3.3% in the fourth quarter. FourThought Financial Partners LLC now owns 1,076 shares of the medical technology company’s stock worth $322,000 after acquiring an additional 34 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.
Stryker Trading Down 0.8 %
Shares of Stryker stock opened at $327.45 on Thursday. The company’s fifty day moving average is $338.89 and its two-hundred day moving average is $339.52. Stryker Co. has a 1 year low of $249.98 and a 1 year high of $361.41. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.99 and a current ratio of 1.71. The company has a market capitalization of $124.74 billion, a P/E ratio of 37.38, a PEG ratio of 2.60 and a beta of 0.89.
Stryker Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th were issued a $0.80 dividend. This represents a $3.20 annualized dividend and a dividend yield of 0.98%. The ex-dividend date was Friday, June 28th. Stryker’s payout ratio is 36.53%.
Analysts Set New Price Targets
SYK has been the topic of several recent research reports. UBS Group lifted their target price on shares of Stryker from $351.00 to $366.00 and gave the stock a “neutral” rating in a research note on Wednesday. Morgan Stanley raised their price target on shares of Stryker from $345.00 to $350.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Robert W. Baird upped their price objective on Stryker from $367.00 to $378.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. TD Cowen lifted their target price on Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Finally, Stifel Nicolaus cut their price objective on Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a research report on Wednesday. Four analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $371.74.
Get Our Latest Research Report on Stryker
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
See Also
- Five stocks we like better than Stryker
- Why is the Ex-Dividend Date Significant to Investors?
- Procter & Gamble Stock Drops Despite Earnings Beat – What to Know
- What is the Shanghai Stock Exchange Composite Index?
- Financial Sector Shines as Key Players Continue to Beat Earnings
- The 3 Best Fintech Stocks to Buy Now
- Russell 2000 Index Bull Run: This ETF is Poised for Growth
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.